Dear <<First Name>>,

Welcome to the latest TB Modelling and Analysis Consortium (TB MAC) newsletter, with information for TB modellers, epidemiologists, and decision-makers. This newsletter contains information on available funding for the TB MAC modelling course at the Union Conference, a job opportunity with Harvard Medical School and papers from our community.

Funding available: Do you know someone who would like to attend an Introduction to TB Modelling Course at the Union Conference?

Participants looking for an introduction to the basic structure, assumptions, principles, and concepts of TB modelling, look no further. TB MAC's Post Graduate course - 'An Introduction to Tuberculosis Modelling' - has been accepted to this year's Union Conference The course will take place on Tuesday 14 November, from 08:00 to 14:00 CET in room 242 B (TR). We are able to cover the registration costs for up to 10 people to attend this course for individuals from low and middle income countries (normally ~Euro100). To apply for this funding, please email us at tb-mac@lshtm.ac.uk and include your current institution and country, as well as a brief paragraph justifying your interest. Successful applications will be notified on a weekly basis. Please pass on the details of this course to anyone you think would be interested.

Join us for a TB MAC social at the Union Conference, on Thursday 16th November

Please pencil in the evening of Thursday 16th November to join us in-person at the Union conference in Paris, for an informal gathering of the TB modelling and analysis community. Venue and time to be confirmed. We hope to see you there!

Join our next TB MAC seminar: Juan Vesga and Kevin Schwartzman presenting on Drivers, potential impact, costs, and cost-effectiveness of scaling up target regimens for TB preventive therapy [31st August 1400-1500 BST]

TB MAC would like to invite you to join us for a seminar on A long and winding road: drivers, potential impact, costs, and cost-effectiveness of scaling up target regimens for TB preventive therapy, given by members of the TB MAC community, Juan Vesga and Kevin Schwartzman on the **31st August 1400-1500 BST**. See below for more details on the seminar, presenter and how to join and add this event to your calendar.

Seminar summary:

The End TB Strategy has focused the attention of affected communities, providers, policymakers, researchers and modellers on the treatment of TB infection in diverse settings. In 2020, WHO published target product profiles for TB preventive therapy. These reflected consensus from a technical consultation, which was further informed by epidemiologic modelling and attribution of potential costs and

cost-effectiveness, using several countries as case studies. In our presentation, we will review some key steps, methods, and findings of this work.

Presenter bios:

Juan Vesga is an infectious disease epidemiologist with a strong background in public health, mathematical modelling and data analysis. He joined LSHTM in August 2021 to work on modelling emerging infections and vaccine evaluation, with Prof John Edmunds. Before joining the School he was part of the Tuberculosis Modelling Group at Imperial College London. He has also worked as lead epidemiologist in the private sector, using microsimulation methods to assess the future burden of non-communicable diseases.

Kevin Schwartzman is a pulmonologist with a clinical and research focus on TB, particularly the use of decision analysis modelling and cost-effectiveness analyses to evaluate TB prevention programs. His ongoing work examines the use of broadened screening and other potential strategies to reduce the burden of TB disease in Canada's foreign-born population. From 2014-2023 he served as director of the Respiratory Division at McGill University (Montreal, Canada), where he is now Associate Chair for Research as well as Professor - both in the Department of Medicine at McGill.

Joining details:

The seminar will take place online on the **31st August 1400-1500 BST**, Dial-in details:
https://lshtm.zoom.us/j/96829797207?pwd=VXA3ZVFxZnFPZHdkQi9SSTRPTWR0Zz09
Meeting ID: 968 2979 7207
Password: 734415

Click below to add the event to your calendar and ensure you don't miss out!

Apple Google Office 365 Outlook Outlook.com Yahoo

Job opportunity: Research Scientist, Massachusetts General Hospital and Harvard Medical School
The Medical Practice Evaluation Center (MPEC) at Massachusetts General Hospital and Harvard Medical School has an opportunity for an enthusiastic and energetic individual to join our research team investigating the clinical and economic value of alternative strategies of HIV and tuberculosis diagnosis, treatment, and prevention, as well as modeling of other diseases and care. Qualifications include: (1) PhD or ScD in Operations Research, Decision Science, Systems Engineering, Industrial Engineering, Biostatistics, Epidemiology, or related area; (2) minimum of 5 years of research experience (inclusive of graduate studies). The candidate should be highly motivated with extensive experience in quantitative methods, independent mathematical model development, parameterization, and debugging. A more detailed job description and instructions for applying are here.

Papers:

Mandal et al estimate the burden of TB in India

Rosu et al estimate the cost of treatment support for MDR-TB using patient-centred approaches in Ethiopia

Xu et al calculate the cost-Effectiveness of bedaquiline-containing regimen for MDR-TB in China

Mmamapudi et al evaluate drivers of sex differences in South African adult TB burden over time

Kim et al estimate the global burden of attributable and associated bacterial AMR avertable by vaccination

Portnoy et al estimate the potential impact of novel vaccines on health equity and financial protection in LMICs

Portnoy et al calculate the potential impact of novel vaccines on economic growth in LMICs

Ling et al estimate the effect of diabetes mellitus on TB in eastern China

Cavalcanti et al evaluate the association of conditional cash transfer with child mortality in Latin America

Fekadu et al calculate the cost-effectiveness of standard diagnostics with and without urine-based LAM testing for TB disease in HIV-infected patients in South Africa

Ojo et al develop statistical models for TB projections in Africa

Ryckman et al model the impact and cost-effectiveness of short-course TB preventive treatment for household contacts and people with HIV in 29 high-incidence countries

For more information on TB MAC, or to get involved, please contact any of the TB MAC Committee, visit www.tb-mac.org or email us directly at tb-mac@lshtm.ac.uk.

Best wishes,

Richard, Finn, Christina and the TB MAC Committee

www.tb-mac.org

tb-mac@lshtm.ac.uk

GDPR compliance

In line with the new European data protection regulations (GDPR), we would like to make sure that you still want to hear from us and keep receiving the newsletter. Subscription to the newsletter means we have your name, email and organisation details stored in a private mailing list. If you no longer like us to keep this information or no longer wish to receive newsletters please click on unsubscribe below. Should you choose not to unsubscribe we will take this as your acceptance to continue receiving newsletters from us.

Tweet   Forward

unsubscribe from this list   update subscription preferences